

# Transient Elastography

Policy Number: PA-101  
Last Review Date: 05/09/2019  
Effective Date: 07/01/2019

## Policy

Evolent Health considers **Transient Elastography (TE)** (e.g., FibroScan) medically necessary for the following indications:

- Initial assessment of fibrosis of members with a diagnosis with hepatitis C; or
- Follow-up assessment of fibrosis of members with a diagnosis of hepatitis C and previously documented F0, F1, or F2 per METAVIR staging guidelines; or
- Assessment of advanced fibrosis (F2 or greater) versus minimal or no fibrosis (F1 or F0)

*NOTE: TE is considered experimental and investigational for all other indications.*

## A. Limitations

TE (e.g. FibroScan) is considered not medically necessary and is therefore not covered if the member meets any of the following criteria:

- BMI of <19 kg/m<sup>2</sup> or >30 kg/m<sup>2</sup>
- Ascites
- Focal lesions within the liver (e.g., tumor)
- Acute liver injury
- Previously documented liver fibrosis of F3 or F4
- Pregnant
- Alanine transaminase (ALT) level five or more times the upper limit of normal (55 units per liter )
- Implanted metal device (e.g., pacemaker, automated implantable cardioverter defibrillator (AICD), or any other implantable defibrillators)
- TE performed within the previous 12 months
- Liver biopsy within the previous six months

## Background

Fibrosis is a scarring process that replaces damaged liver cells, causing inflammation and leading to the formation of fibrous scar tissue in the liver. Transient Elastography (TE) is a non-invasive technique for the evaluation of fibrosis in chronic liver disease. TE serves as an alternative to liver biopsy, the gold standard for evaluating liver fibrosis. TE measures liver stiffness by tracking the wave speed through ultrasound.

The only system suitable for performing TE is the FibroScan System (Echosens SA; Paris, France), as approved by the US FDA on April 5, 2013.

## METAVIR Scoring System

## Transient Elastography (e.g., FibroScan)

Policy Number: PA-101  
 Last Review Date: 05/09/2019  
 Effective Date: 07/01/2019

Activity Grade	
A0	No activity
A1	Mild activity
A2	Moderate activity
A3	Severe activity
Fibrosis Stage	
F0	No fibrosis
F1	Stellate enlargement of portal tract but without septa formation
F2	Enlargement of portal tract with rare septa formation
F3	Numerous septa without cirrhosis
F4	Cirrhosis

### Code:

91200	Liver elastography, mechanically induced shear wave (e.g., vibration), without imaging, with interpretation and report
-------	--

### References

1. Afdahl NH. Fibroscan (transient elastography) for the measurement of liver fibrosis. *Gastroenterol Hepatol (NY)*. 2012 Sep;8(9):605-607. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594956/>
2. Castera L, Foucher L, Bernard PH, et al. . Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. *Hepatology*. 2010 Mar;51(3):828-835. doi: 10.1002/hep.23425. <http://onlinelibrary.wiley.com/doi/10.1002/hep.23425/full>
3. Crespo G, Fernandez-Varo G, Marino Z, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. *J Hepatol*. 2012 Aug;57(2):281-287. doi: 10.1016/j.jhep.2012.03.016. Epub 2012 Apr 17. <http://www.sciencedirect.com/science/article/pii/S0168827812002711>
4. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). *J Hepatol*. 2010 Dec;53(6):1013-1021. doi: 10.1016/j.jhep.2010.05.035. Epub 2010 Aug 14. <http://www.sciencedirect.com/science/article/pii/S0168827810006926>
5. Foucher J, Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. *Gut*. 2006 Mar;55(3):403-408. Epub 2005 Jul 14. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1856085/>

## Transient Elastography (e.g., FibroScan)

Policy Number: PA-101  
Last Review Date: 05/09/2019  
Effective Date: 07/01/2019

6. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. *Gastroenterology*. 2008 Apr;134(4):960-974. doi: 10.1053/j.gastro.2008.01.034. Epub 2008 Jan 18. <http://www.sciencedirect.com/science/article/pii/S001650850800108X>
7. Hayes Medical Technology Directory. Ultrasound Transient Elastography for Detecting Hepatic Fibrosis in Patients with Hepatitis C. Publication Date: March 27, 2019.
8. HepatitisCentral.com. Table 4. The METAVIR System. Algorithm for Evaluation of Histological Activity. Copyright ©1994-2019 Hepatitis Central. Available at: <http://www.hepatitiscentral.com/hcv/biopsy/charts/metavir.html>
9. Kemp W, Roberts S. FibroScan® and transient elastography. *Aust Fam Physician*. 2013 Jul;42(7):468-471. <http://www.racgp.org.au/afp/2013/july/fibroscan/>
10. U.S. Food and Drug Administration (FDA). Echosens' FibroScan® System. 510(k) Summary. K123806. Approved: Apr. 5, 2013. (Manufacturer: Echosens SA). [https://www.accessdata.fda.gov/cdrh\\_docs/pdf12/k123806.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf12/k123806.pdf)
11. Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). *Gastroenterol Rep (Oxf)*. 2013 Jul;1(1):19-26. doi: 10.1093/gastro/got007. Epub 2013 Mar 26. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941434/>

### Disclaimer:

Evolent Health medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Evolent Health and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Evolent Health reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Evolent Health. Any sale, copying, or dissemination of said policies is prohibited.